IMRX
Immuneering CorpNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$338.13M
P/E Ratio
—
EPS
$-1.23
Beta
0.43
52W High
$10.08
52W Low
$1.10
50-Day MA
$5.08
200-Day MA
$5.48
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Immuneering Corp
Immuneering Corp (IMRX) is a pioneering biotechnology company focused on the development of innovative therapeutics for cancer and other severe diseases using its proprietary drug discovery platforms. By leveraging advanced bioinformatics and machine learning, Immuneering excels in identifying and optimizing drug candidates that precisely target critical biological pathways, thereby enhancing patient outcomes with therapies that are both more effective and less toxic. With a robust pipeline of drug candidates and strategic collaborations, the company is well-positioned to emerge as a leader in the rapidly evolving landscape of personalized medicine and targeted cancer therapies.
Fundamentals
| Revenue (TTM) | 455 |
| Gross Profit (TTM) | 158,830 |
| EBITDA | $-59.02M |
| Operating Margin | 0.00% |
| Return on Equity | -43.10% |
| Return on Assets | -26.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.38 |
| Price-to-Book | 1.62 |
| Price-to-Sales (TTM) | 563.62 |
| EV/Revenue | 191913.54 |
| EV/EBITDA | -1.53 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.80% |
| Shares Outstanding | $64.65M |
| Float | $49.40M |
| % Insiders | 17.83% |
| % Institutions | 50.74% |
Analyst Ratings
Consensus ($17.00 target)
2
Strong Buy4
BuyData last updated: 4/8/2026